TAK-411

Phase 2Biologic

TAK-411 is one of 6 biologic programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Approved

1 2

Riliprubart

Sanofi

Phase 3

1 3

TAK-881

Takeda

Phase 3

1 4

HYQVIA

Takeda

Phase 3

2 5

Gazyva

Roche

Preclinical

1 6

TAK-411

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06798012

Clinical

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting· Takeda logo

Takeda·Phase 2·NCT06798012·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAK-411. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-411 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-411. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-411

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

References

Drug Info

Quick Facts

Related News